3013
Transcreener® ADP2 FI Assay
Synonym(s):
ADP Assay Kit, Transcreener ADP Assay
Sign Into View Organizational & Contract Pricing
All Photos(1)
About This Item
UNSPSC Code:
41122100
NACRES:
NA.84
Recommended Products
shipped in
dry ice
storage temp.
−20°C
General description
The Transcreener® HTS Assay platform overcomes the need for time-consuming, one-off assay development for individual members within a group transfer enzyme family by utilizing a single set of assay reagents that detect an invariant product. The generic nature of the Transcreener® HTS Assay platform eliminates delays involved in assay development for new HTS targets, and greatly simplifies compound and inhibitor profiling across multiple target families.
The Transcreener® ADP2 fluorescent intensity (FI) assay extends the Transcreener® platform for ADP detection by utilizing a simple fluorescent intensity output which can be used on both fluorescence readers typically found in academic and therapeutic research labs as well as more complex multimode plate readers more commonly used in core facilities and HTS labs. The Transcreener® ADP2 FI Assay is a red, competitive fluorescence intensity (FI) assay based on the detection of ADP and therefore is compatible with any enzyme class that produces ADP, including protein, lipid, and carbohydrate kinases, ATPases, DNA helicases, carboxylases and glutamine synthetase. The Transcreener® ADP2 Assay is a simple one step homogenous detection assay, and is flexible with regard to ATP concentration (0.1 to 100 μM ATP). The assay provides excellent signal at low substrate conversion, with a Z′ = 0.7 at 2.5% ATP conversion using 1 μM ATP.
The Transcreener® ADP2 FI Assay was developed to follow the progress of any enzyme that produces ADP. The Transcreener® ADP Detection Mixture comprises a quenched ADP Alexa594 Tracer bound to the ADP2 monoclonal antibody conjugated to an IRDye® QC-1 quencher licensed from LI-COR®. The tracer is displaced by ADP, the invariant product generated during an enzyme reaction. The displaced tracer becomes un-quenched in solution leading to a positive increase in fluorescence intensity. Therefore, ADP production is proportional to an increase in fluorescence. The red tracer minimizes interference from fluorescent compounds and light scattering.
View full Transcreener® product list
The Transcreener® ADP2 fluorescent intensity (FI) assay extends the Transcreener® platform for ADP detection by utilizing a simple fluorescent intensity output which can be used on both fluorescence readers typically found in academic and therapeutic research labs as well as more complex multimode plate readers more commonly used in core facilities and HTS labs. The Transcreener® ADP2 FI Assay is a red, competitive fluorescence intensity (FI) assay based on the detection of ADP and therefore is compatible with any enzyme class that produces ADP, including protein, lipid, and carbohydrate kinases, ATPases, DNA helicases, carboxylases and glutamine synthetase. The Transcreener® ADP2 Assay is a simple one step homogenous detection assay, and is flexible with regard to ATP concentration (0.1 to 100 μM ATP). The assay provides excellent signal at low substrate conversion, with a Z′ = 0.7 at 2.5% ATP conversion using 1 μM ATP.
The Transcreener® ADP2 FI Assay was developed to follow the progress of any enzyme that produces ADP. The Transcreener® ADP Detection Mixture comprises a quenched ADP Alexa594 Tracer bound to the ADP2 monoclonal antibody conjugated to an IRDye® QC-1 quencher licensed from LI-COR®. The tracer is displaced by ADP, the invariant product generated during an enzyme reaction. The displaced tracer becomes un-quenched in solution leading to a positive increase in fluorescence intensity. Therefore, ADP production is proportional to an increase in fluorescence. The red tracer minimizes interference from fluorescent compounds and light scattering.
View full Transcreener® product list
Quantity
3013-A = 200 assay, 96-well
3013-1K = 1,000 assay, 384-well
3013-10K = 10,000 assay, 384-well
3013-1K = 1,000 assay, 384-well
3013-10K = 10,000 assay, 384-well
Physical form
Kit with buffered aqueous solutions
Legal Information
IRDye is a registered trademark of LI-COR, Inc.
LI-COR is a registered trademark of LI-COR, Inc.
Transcreener is a registered trademark of BellBrook Labs
Signal Word
Warning
Hazard Statements
Precautionary Statements
Hazard Classifications
Eye Irrit. 2
Storage Class Code
12 - Non Combustible Liquids
WGK
WGK 3
Flash Point(F)
Not applicable
Flash Point(C)
Not applicable
Certificates of Analysis (COA)
Search for Certificates of Analysis (COA) by entering the products Lot/Batch Number. Lot and Batch Numbers can be found on a product’s label following the words ‘Lot’ or ‘Batch’.
Already Own This Product?
Find documentation for the products that you have recently purchased in the Document Library.
Elizabeth Londoño-Velasco et al.
Biomedica : revista del Instituto Nacional de Salud, 39(3), 464-477 (2019-10-05)
Introduction: The exposure to organic solvents and paints has been associated with genotoxicity and a greater risk of neoplasms. However, the type of DNA damage induced in humans by the exposure to these compounds, which would help explain the mechanisms
John M Pisciotta et al.
The Biochemical journal, 402(1), 197-204 (2006-10-19)
The intraerythrocytic malaria parasite constructs an intracellular haem crystal, called haemozoin, within an acidic digestive vacuole where haemoglobin is degraded. Haem crystallization is the target of the widely used antimalarial quinoline drugs. The intracellular mechanism of molecular initiation of haem
Siwen Bi et al.
Polymers, 12(2) (2020-02-07)
In this work, biodegradable polymers were melt compounded with urea phosphate to fabricate "smart fertilizers" for sustainable agriculture. Urea phosphate (UP) is typically applied as a water-soluble fertilizer to treat phosphorus deficiency in high pH soils. Due to the low
Sungsoon Fang et al.
Nature medicine, 21(2), 159-165 (2015-01-07)
The systemic expression of the bile acid (BA) sensor farnesoid X receptor (FXR) has led to promising new therapies targeting cholesterol metabolism, triglyceride production, hepatic steatosis and biliary cholestasis. In contrast to systemic therapy, bile acid release during a meal
Yasuhiro Uno et al.
Biochemical pharmacology, 174, 113835-113835 (2020-02-07)
The common marmoset is an important primate species used in drug metabolism studies. However, glutathione S-transferases (GSTs), essential drug-metabolizing enzymes involved in the conjugation of various endogenous and exogenous substrates, have not been identified or characterized in this species. In
Our team of scientists has experience in all areas of research including Life Science, Material Science, Chemical Synthesis, Chromatography, Analytical and many others.
Contact Technical Service